Switching to the Dry-Powder Inhaler Easyhaler®: A Narrative Review of the Evidence

Federico Lavorini · Jerzy Chudek · Gabriella Gálffy · Abel Pallarés-Sanmartin · Anna S. Pelkonen · Paula Rytilä · Jörgen Syk · Maria Szilasi · Lilla Tamási · Athanasios Xanthopoulos · Tari Haahtela

Received: July 19, 2021 / Accepted: September 7, 2021 / Published online: September 27, 2021 © The Author(s) 2021

ABSTRACT

Asthma and chronic obstructive pulmonary disease (COPD) are major causes of morbidity and mortality worldwide. Optimal control of these conditions is a constant challenge for both physicians and patients. Poor inhaler practice is widespread and is a substantial contributing factor to the suboptimal clinical control of both conditions. The practicality, dependability, and acceptability of different inhalers influence the overall effectiveness and success of inhalation therapy. In this paper, experts from various European countries (Finland, Germany, Hungary, Italy, Poland, Spain, and Sweden) address inhaler selection with special focus on the Easyhaler® device, a high- or medium–high resistance dry-powder inhaler (DPI). The evidence examined indicates that use of the Easyhaler is associated with effective control of asthma or COPD, as shown by the generally accepted indicators of

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s41030-021-00174-5.

F. Lavorini
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

J. Chudek
Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland

G. Gálffy
Pulmonary Hospital, Törökbálint, Hungary

A. Pallarés-Sanmartin
Respiratory Department, Hospital Montecelo, University Hospital Complex, Pontevedra, Spain

A. S. Pelkonen · T. Haahtela
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland

P. Rytilä
Global Medical Affairs, R&D, Orion Pharma, PO Box 65, 02101 Espoo, Finland
e-mail: paula.rytila@orionpharma.com

J. Syk
Academic Primary Health Care Centre, Stockholm, Sweden

J. Syk
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

J. Syk
Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden

M. Szilasi
National Korányi Institute of Pulmonology, Budapest, Hungary

L. Tamási
Department of Pulmonology, Semmelweis University, Budapest, Hungary

A. Xanthopoulos
Praxis für Pneumologie, Fürstenwalde, Germany
treatment success. Moreover, the Easyhaler is widely accepted by patients, is reported to be easy to learn and teach, and is associated with patient adherence. These advantages help patient education regarding correct inhaler use and the rational selection of drugs and devices. We conclude that switching inhaler device to the Easyhaler may improve asthma and COPD control without causing any additional risks. In an era of climate change, switching from pressurized metered-dose inhalers to DPIs is also a cost-effective way to reduce emissions of greenhouse gases.

Enhanced feature (slides, video, animation) (MP4 43768 kb)

**Keywords:** Adherence; Asthma; Compliance; COPD; Dry-powder inhaler; Easyhaler; Patient-centered outcomes; Pressurized metered-dose inhaler; Respiratory function

### Key Summary Points

**Success in treating asthma and chronic obstructive pulmonary disease (COPD) may depend on inhaler choice.**

**Correct use of the Easyhaler® dry-powder inhaler (DPI) is less dependent on patients’ hand–breath coordination than use of a pressurized metered-dose inhaler (pMDI).**

The Easyhaler delivers medication consistently and reliably at low respiratory rates (≤ 30 l/min) and inhalation volumes (down to 0.5 l), making it suitable for the majority of asthma and COPD patients.

In clinical studies, patients often express a preference for the Easyhaler over pMDIs and other devices. They report that it is easy to learn and use.

Switching an inhaler device to the Easyhaler may improve asthma and COPD control and can be done safely. Preferring DPIs to pMDIs is also a cost-effective way to reduce emissions of greenhouse gases.

### DIGITAL FEATURES

This article is published with digital features, including a video abstract, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.16578746.

### INTRODUCTION

Asthma and chronic obstructive pulmonary disease (COPD) are widespread illnesses that impose significant morbidity and mortality burdens in countries around the world. COPD is in fact one of the top five causes of death worldwide [1, 2]. Both conditions also exert substantial socioeconomic impacts through their effects on productivity and erosion of quality of life [3]. Although an elaborate array of pharmacologic treatments is available and widely recommended in expert guidelines, both asthma and COPD remain uncontrolled in a substantial proportion of patients [4, 5] and one factor contributing to this situation is suboptimal adherence to treatment.

Given that many therapies for asthma and COPD are delivered by inhalation, incorrect and/or inconsistent inhaler use may have a substantial influence on treatment efficacy. Poor inhaler practice is widespread in the treatment of asthma and COPD and reports on this matter may even under-represent the true situation since many patients’ suboptimal technique may go unidentified for lengthy periods of time. This phenomenon has been apparent since the introduction of inhalers, with little evidence of any sustained improvement over time [6].

As recently articulated by Kaplan and van Boven [7] in the principles of the UR-RADAR concept, the selection and switching of inhalers should be considered within a wider framework of clinical evaluation and patient engagement. Notwithstanding acknowledged differences between different devices with regard to release mechanism, drug particle size and deposition, and required inspiratory flow, the optimal matching of patient and inhaler can exert a powerful influence on the overall clinical
success of a treatment strategy in these chronic respiratory diseases [8–12]. Similarly, switching requires careful consideration and is not a process to be undertaken without patient consent and retraining in the correct use of a novel device.

In this paper, experts from various European countries (Finland, Germany, Hungary, Italy, Poland, Spain, and Sweden) address some of the issues involved in inhaler selection and device switching with special focus on the Easyhaler® dry powder inhaler (DPI).

This article is based on previously conducted studies and does not contain details of any new studies with human participants or animals performed by any of the authors.

TECHNICAL AND THEORETICAL ASPECTS OF INHALER DEVICES

A brief consideration of the relative advantages of different types of inhaler is appropriate. A full treatment of the options is beyond the scope of this short review, which focuses on pressurized metered-dose inhalers (pMDIs) and dry-powder inhalers (DPIs), the latter being specifically exemplified by the Easyhaler® dry powder inhaler (DPI).

Is the Easyhaler Different?

In contrast to pMDIs, the drug dose of DPIs such as Easyhaler is released by force generated by the patient’s inhalation (Fig. 1). The requirement of coordination—and the clinical consequences of poor coordination—is mitigated. During each inhalation, a turbulent airflow is created inside the DPI by the interaction between the patient’s inhalation maneuver and the resistance inside the device. The kinetic energy of the turbulent airflow breaks up the drug powder and separates/de-aggregates the drug particles from the carrier particles (usually lactose). For this reason, high- or medium–high-resistance DPIs are poised to provide a more favorable set of inhalation characteristics for drug de-aggregation and delivery of the inhaled dose into the lungs than lower-resistance DPIs [17].

A corollary of this phenomena is that inhalation sufficiently forceful to de-aggregate the powdered drug into breathable-sized particles (European Pharmaceutical limit of the aerodynamic diameter < 5 μm ca.) is required to guarantee drug delivery distal to the oropharynx to deposit at the airways of the lungs. Compared with pMDIs, DPIs require fast and strong inhalation.

Prima facie, this would seem to be a limitation of DPIs for younger asthmatic patients or for COPD patients, at least some of whom have often struggle with device activation timing, as was illustrated in the CRITIKAL trial, which identified actuation before inhalation in 24.9% of patients and associated that wrong practice with uncontrolled asthma (odds ratio [OR] 1.55, 95% confidence interval [CI] 1.11–2.16) [15]. In some cases, due to the hand–breath coordination challenge, patients are prescribed, or advised to use, an additional spacer device for administration of the drug, which represents an additional source of user-generated errors or at least an additional inconvenience such as reduced portability of the pMDI, the need to wash the spacer regularly (although not in the case of extra-fine-particle pMDIs) and, last but not least, an extra cost [16].
reduced inspiratory force. In clinical practice, however, good drug delivery via the Easyhaler DPI has been demonstrated in a series of studies in asthmatic children and adults with COPD at peak inspiratory flow rates (PIFRs) as low as 28 l/min, a threshold level attainable by the majority of patients with both conditions [18–21]. In a recent randomized, open-label, crossover study [22] in 100 patients with COPD and 100 healthy volunteers, it was shown that the Easyhaler was preferred by 51% of patients, while 25% favored the comparator (HandiHaler®/C210®). In comparison to the other DPIs (e.g., Turbuhaler®/C210®), a greater consistency of drug dose delivery has been recorded with the Easyhaler across a wide range of PIFRs (Fig. 2). The variability in dose delivery with the Easyhaler was significantly smaller than that with Turbuhaler (\(p < 0.001\)) and Diskus® (\(p < 0.001\)) [23].

**Clinical Effectiveness at Low Inspiration Rates**

The ability of the Easyhaler to deliver clinically relevant improvements in spirometry indices in patients with relatively low inspiration rates was also demonstrated in a double-blind, randomized, cross-over study in 21 pediatric or adult patients with asthma who were switched between the Easyhaler or a pMDI-plus-spacer arrangement. The active therapeutic compound in each case was salbutamol (dose of 100 µg) [24]. The average PIFR through the Easyhaler was 28.7 l/min. Before and after Easyhaler use, peak forced expiratory volume in 1 s (FEV1) was 2.44 ± 0.90 and 2.69 ± 0.93 l, respectively, compared with 2.43 ± 0.90 and 2.67 ± 0.97 l, respectively, after administration of salbutamol via pMDI-plus-spacer. Both post-treatment values were significantly larger than the respective pre-treatment values (\(p < 0.05\)), with no significant difference between groups up to 60 min after inhalation. Similarly, Malmstrom et al. [17] reported during development of the Easyhaler that the clinical bronchodilator effect of gain of salbutamol (200 µg) delivered via this DPI was equivalent to that from an un-primed MDI with a spacer in children with asthma, including a subset of 15 patients with bronchial obstruction (defined as peak expiratory flow < 85% of predicted).

**Clinical Effectiveness at Low Inspiration Volumes**

The inhalation volume required for complete dose delivery is also an important consideration because a low inhalation volume may reduce the delivered dose of medication. In vitro assessments indicated that the delivered dose of budesonide/formoterol provided via the Easyhaler was independent of inhalation volume down to 0.5 l, although the formoterol component was decreased by 10% (\(p < 0.0125\)) at 0.25 l when a low-dose combination was tested. Delivered dose declined more markedly, and at higher inhalation volumes, for some other DPIs evaluated in this way. These data are particularly relevant to the management of COPD patients, who often have low (< 1 l) inhalation volumes, and provide some assurance that drug delivery from the Easyhaler is likely to be as
predicted and sufficient in a large percentage of cases [14].

**Robust Practical Performance**

In a very recently reported non-comparative in vitro assessment of the salmeterol–fluticasone propionate Easyhaler (50/250 or 50/500 µg per dose) [25], performance, as quantified by the delivered drug dose (DD) and fine-particle dose, remained consistent throughout the lifespan of the inhaler (60 doses) and was unaffected by simulated environmental stress. Drug delivery remained unchanged with or without drooping (DD ranging from 99 to 104% for salmeterol and from 95 to 103% for fluticasone, when setting the initial dose values to 100%), vibration (DD after test: 100–102% and 97–100% for salmeterol and fluticasone, respectively), exposure to moisture (DD after test: 98–102% and 98–107% for salmeterol and fluticasone, respectively) and freeze–thawing (DD after test: 100–101% and 99–101% for salmeterol and fluticasone, respectively). Moreover, no inhaler breakages occurred during these tests, confirming the robustness of the device.

---

**A Wider View on Values: Sustainability**

Healthcare is one of the major contributors to emissions of greenhouse gases, and climate breakdown threatens to undo many of the advances in public health achieved over the last 50 years. Therefore, efforts to reach net-zero emissions of greenhouse gases from healthcare are vital [26]. The carbon footprint of inhaled treatments has come under scrutiny recently, largely due to the greenhouse-gas effect of hydrofluoroalkane propellants used in MDIs [27]. These propellants are powerful greenhouse gases (from 1500 to 3000 times greater global warming potential than CO₂ [28]), and so have a disproportionate impact on the carbon footprint of treatment. In the UK for instance, MDIs contribute 13% of the core carbon footprint of the National Health Service (NHS) related to delivery of care, and 3% of the “carbon footprint plus” emissions which the NHS can influence [29].

Switching to low-carbon inhalers, such as DPIs, has been identified as a key strategy for the NHS to achieve net zero carbon emissions. Life-cycle analysis of the Easyhaler shows it to have a carbon footprint of 0.58 kg CO₂ equivalent per device, a burden much smaller than that of MDIs, which ranges from 9 to 37 kg CO₂.
equivalent per device [30, 31]. Where clinically appropriate, switching to DPI devices such as the Easyhaler has been proposed as a cost-effective way to reduce emissions of greenhouse gases from MDIs [32].

CLINICAL OBSERVATIONS AND REAL-WORLD EXPERIENCE

Some of the issues involved in inhaler selection and device switching—with special focus on the Easyhaler device—were addressed in a series of recent clinical trials (see Table 1 for a synopsis).

Tamási, Szilasi, and Gálffy [33] have recently presented ‘real-world’ data on the effectiveness of the budesonide/formoterol drug combination in the management of asthma or COPD when administered via Easyhaler. In the same study, use of the Easyhaler was associated with high levels of patient satisfaction. These insights emerged from a multicenter, open-label, non-randomized, non-interventional study conducted at 200 centers in Hungary and involving a total of 1498 adult patients (average age > 50 years; asthma: n = 621; COPD: n = 778; asthma–COPD overlap: n = 99), of whom 455 (30.4%) were newly diagnosed, inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers (Turbuhaler or Diskus DPIs, or pMDIs). The medications administered in the study were budesonide (160 or 320 µg per inhalation) or formoterol (4.5 or 9 µg per inhalation, respectively), with a dose depending on the frequency of administration of medications at baseline.

Most of the enrolled patients (n = 1043) had poorly controlled asthma or experienced a high impact of COPD on their daily lives and were using a maintenance medication at baseline. Treatment effectiveness was assessed after 12 weeks of treatment using spirometry and a range of established condition-appropriate tests. Patient satisfaction with the Easyhaler (on a six-point scale) and physicians’ assessments of ease of use and time taken to learn the DPI technique were also assessed.

Impact on Clinical Respiratory Indices

Significant improvements in lung function, disease control, and health-related quality of life measures (p ≤ 0.01 for all) were reported after 12 weeks of Easyhaler use among both inhaler-naïve patients and those who switched from other devices. By that time, 73.2% of all patients with asthma (asthma and asthma–COPD overlap) were described as ‘well controlled’ in the conclusion of the study. Among patients with asthma, use of reliever inhaler decreased markedly, with 87.2% of patients reporting at week 12 that they used the reliever no more than once a week, compared with 32.2% of patients at baseline. Among patients with COPD, the average COPD Assessment Test score declined from 24.2 ± 5.7 at baseline to 18.2 ± 5.1 at the end of the study (p < 0.001) [33].

High Patient Satisfaction with the Easyhaler

Among the switching patients, 97.2% self-reported very high satisfaction with the Easyhaler (score of one on the six-point scale), compared with < 20% for pre-study devices (Fig. 3). In addition, > 90% of physicians categorized the Easyhaler as very easy (57.7%) or easy (35.3%) to teach, with a similar proportion reporting a teaching time of ≤ 10 min [33].

A supplementary analysis in which 961 asthma or COPD patients were stratified according to the inhaler device used at baseline confirmed the general findings of this investigation [34]. Specifically, this analysis documented significant improvements in multiple dimensions of patients’ clinical status in both asthma and COPD patients after switching to Easyhaler-delivered medications (Fig. 4).

Notable features of this study were that (a) patients whose proficiency with usage of their previously prescribed inhaler was considered unsatisfactory, or who did not feel comfortable with their device, were eligible to participate and (b) training in use of the Easyhaler was to the standard likely to be encountered in routine care rather than the more
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Aim</th>
<th>Study design and population</th>
<th>Study characteristics</th>
<th>Study results</th>
<th>Main outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syk et al. [53]</td>
<td>Sweden</td>
<td>Real-life comparison in asthma patients on budesonide/formoterol treatment switching device from Turbuhaler to Easyhaler</td>
<td>Real-life, non-interventional, non-inferiority study in adults with persistent asthma ($n = 117$)</td>
<td>A baseline visit (demographic and endpoint data were recorded, and eligible patients switched to B/F Easyhaler), was followed by a control visit and a concluding examination visit after 12 weeks. Asthma control was assessed using the Asthma Control Test. The mini-Asthma Quality of Life Questionnaire and lung function test were also performed. Moreover, participants and investigators answered questionnaires about ease of learning and ease of use</td>
<td>At visit 3, B/F Easyhaler demonstrated non-inferiority to B/F Turbuhaler; the mean difference in change from baseline ACT was statistically significant (18.9 vs. 20.7, respectively; $p &lt; 0.0001$) and met the non-inferiority criterion of B/F Easyhaler being greater than −1.5 points better than the reference product. Asthma was well controlled in 62 patients (53.0%) at baseline, increasing to 83 (70.9%) at visit 3. Patients experienced statistically significant improvements in mini-AQLQ score after B/F Easyhaler treatment and lung function remained stable across the treatment period. B/F Easyhaler was easy to learn and prepare for use</td>
<td>Asthma patients switching from Symbicort Turbuhaler to Easyhaler had comparable or improved disease control. Patients experienced statistically significant improvements in mini-AQLQ score after B/F Easyhaler treatment and lung function remained stable across the treatment period. B/F Easyhaler was easy to learn and prepare for use</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Aim</td>
<td>Study design and population</td>
<td>Study characteristics</td>
<td>Study results</td>
<td>Main outcome</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Tamasí et al. [33]</td>
<td>Hungary</td>
<td>The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO)</td>
<td>Real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers. A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers</td>
<td>Effectiveness was assessed after 12 weeks of treatment using spirometry, Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnoea scale. Patient satisfaction with the Bufomix Easyhaler and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed</td>
<td>Significant improvements in lung function, disease control, and health-related quality of life measures (p ≤ 0.002 for all) were reported after 12 weeks of Bufomix Easyhaler use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler as ‘very good’ and &gt; 90.0% of physicians described the Bufomix Easyhaler as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively</td>
<td>Patients switching from other inhaler devices to the Easyhaler were more satisfied and achieved improved asthma, COPD, and ACO control in daily clinical practice in outpatient care</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Aim</td>
<td>Study design and population</td>
<td>Study characteristics</td>
<td>Study results</td>
<td>Main outcome</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pirożyński et al. [37]</td>
<td>Poland</td>
<td>To evaluate the clinical effectiveness of a second product (Bufomix Easyhaler) in the daily clinical practice of asthma therapy</td>
<td>Non-randomized, open-label, post-authorization efficacy study. Clinical assessment was conducted by 220 unslected allergologists and pulmonologists who enrolled 2200 adult outpatients (age 49.8 ± 17.9 years) with asthma treated with Bufomix Easyhaler for at least 14 days before enrolment</td>
<td>Asthma control was assessed during three subsequent visits at 8–12-week intervals on the basis of the Asthma Control Test (ACT). Adherence was assessed with the Medication Adherence Questionnaire. In addition, patient satisfaction with the Bufomix Easyhaler was scored, and adverse drug reactions were recorded</td>
<td>The percentage of patients with well-controlled asthma or total control of asthma (ACT score 20–25 points) increased from 46.6% at the first visit to 90.8% at the third visit (p &lt; 0.001). In addition, the percentage of patients with poor control of asthma (ACT score &lt; 15 points) decreased from 14.9 to 1.2% (p &lt; 0.001). The adherence rate increased from 88% at the first visit to 95.3% at the third visit. Patient satisfaction with the use of this dry-powder inhaler increased with the duration of its use</td>
<td>Easyhaler demonstrated good clinical efficacy and improved disease control among adult asthma patients in daily clinical practice in outpatient care</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Aim</td>
<td>Study design and population</td>
<td>Study characteristics</td>
<td>Study results</td>
<td>Main outcome</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-----</td>
<td>-----------------------------</td>
<td>----------------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Price et al. [36]</td>
<td>UK</td>
<td>To investigate the clinical and cost-effectiveness of switching real-life asthma patients from other types of inhaler to the Easyhaler (EH) for the administration of inhaled corticosteroids (ICS)</td>
<td>Historical, matched-cohort study of 1958 asthma patients (children and adults) treated in UK primary-care practices, using data obtained from the Optimum Patient Care Research Database and Clinical Practice Research Datalink. Other inhalers (OH) included pressurized metered-dose inhalers, breath-actuated inhalers and dry-powder inhalers delivering beclomethasone, budesonide, fluticasone, or ciclesonide</td>
<td>Patients who remained on OH unchanged (same drug, dosage and device; n = 979) were matched 1:1 with those who switched to the EH (beclomethasone or budesonide) at the same or lower ICS dosage (n = 979), based on age, sex, year of index patient review/switch, most recent ICS drug dosage and device and the number of severe exacerbations and average daily short-acting β₂ agonist (SABA) dosage in the preceding year. Clinical outcomes and healthcare costs were compared between groups for 12 months before and after the switch</td>
<td>Non-inferiority was shown for the EH for all four co-primary outcomes. There were no significant differences between groups for risk domain asthma control or exacerbation rates, but EH patients were significantly more likely to achieve overall asthma control (adjusted odds ratio [95% confidence interval] 1.26 [1.05–1.52]), as significantly more EH than OH patients had an average SABA dosage of ≤ 200 μg/day (52 vs. 47%; p &lt; 0.001)</td>
<td>Asthma patients may be switched from other ICS devices to Easyhaler with no reduction in clinical effectiveness or increase in healthcare costs</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Aim</td>
<td>Study design and population</td>
<td>Study characteristics</td>
<td>Study results</td>
<td>Main outcome</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gálffy et al. [34]</td>
<td>Hungary</td>
<td>Real-world study aimed to evaluate the effectiveness of budesonide/formoterol fumarate (B/F) Easyhaler in everyday clinical practice in Hungary</td>
<td>Post hoc, subgroup analyses of this 12-week, real-world, multicenter, open-label study were conducted in adults diagnosed with asthma or COPD. In total, 398 and 563 patients with asthma and COPD, respectively, were analyzed</td>
<td>Endpoints included the change in patient-reported outcome measures, i.e., symptoms and disease control measured by the Asthma Control Test or COPD Assessment Test and health-related quality of life (HRQoL) measured by mini-Asthma Quality of Life Questionnaire or modified Medical Research Council dyspnoea scale. Changes in lung function and patient satisfaction with B/F Easyhaler versus previous inhaler were also evaluated. Results were stratified by the inhaler device used at visit 1 (baseline, when patients switched device); comparisons were made with B/F Easyhaler use after 12 weeks, assessed at visit 3</td>
<td>Significant improvements ( p &lt; 0.0001 ) in symptoms and disease control, HRQoL, and lung function were reported 12 weeks after switching treatment to B/F Easyhaler from the most commonly used devices ( \geq 10% ) of patients. Significant increases in patient satisfaction were also reported versus comparators</td>
<td>The use of the Easyhaler is easy to teach. Patients are highly satisfied with the Easyhaler and regard it as easy to learn to use</td>
</tr>
</tbody>
</table>
intensive levels demanded by a randomized, controlled trial.

The findings favoring the Easyhaler may therefore have a degree of pragmatic resilience. On the other hand, part of the positive reception of the Easyhaler may have been due to the patients’ dissatisfaction with their previous inhaler(s). No information was available on baseline education on inhaler training or adherence data for the pre-study devices. Patients’ perceptions of the Easyhaler may therefore have been inflated by prior poor practice or experiences. The lack of a parallel comparator arm is a further limitation, as is the relatively short duration of the study. Longer investigations would need to be established if the initial gains are durable. Gálfy et al. [34] also noted the desirability of further investigation into possible country-specific differences in patient demographics and/or healthcare systems which may influence inhaler usage and/or switching practice.

Additional Clinical Study Findings

Data from other countries are, nevertheless, reassuring regarding the general utility and affirmative impact of Easyhaler use on clinical status in asthma and COPD.

A very recent report from the SUNNY study in Germany and Sweden (NCT03755544) [35] has substantially corroborated the experience of the Hungarian research already described, documenting improved clinical status and high levels of patient adherence and preference for a comparison of visit 1 versus visit 3. ACT Asthma Control Test, CAT COPD Assessment Test. Redrawn after Gálfy et al. [34]
salmeterol–fluticasone regimen delivered by the Easyhaler than by alternative devices in a mixed asthma/COPD population of 231 patients treated for 12 weeks.

Similarly, in the UK, an appraisal of 1958 asthma patients treated in primary care concluded that “Typical asthma patients may be switched from other inhaled corticosteroid devices to the Easyhaler without any reduction in clinical effectiveness or increase in cost.” [36].

In a non-randomized, open-label, post-authorization efficacy study in Poland conducted among 2200 adult (mean age, 49.8 ± 17.9 years) outpatients with asthma, delivery of budesonide/formoterol fumarate via an Easyhaler for 8–12 weeks was associated with an increase in the proportion of patients with well-controlled asthma or total control of asthma (Asthma Control Test [ACT] score 20–25 points) from 46.6 to 90.8% (p < 0.001), and with a marked reduction in the proportion of patients with poor control of asthma (ACT score < 15 points) from 14.9 to 1.2% (p < 0.001) [29]. Patient satisfaction with the Easyhaler increased progressively during the study, as assessed by multiple metrics, including ease of preparation for use, maintenance, incorporation of Easyhaler use into the activities of daily living and the overall physical acceptability of the device (size, weight, portability, etc.) [37].

**Pediatric Clinical Trial Data**

A multicenter, randomized, controlled study conducted at seven hospitals in Thailand to compare the efficacy of salbutamol administered via an Easyhaler, a pMDI with volumatic spacer, or nebulization in mild-to-moderate asthma exacerbations in children aged 5–18 years who presented at an emergency or outpatient department identified no statistically significant differences in the clinical response (assessed using the modified Wood’s asthma score), but less tachycardia among children assigned to the Easyhaler [38].

**Mixed Outcomes in COPD**

To be set against these reports are the findings of Wittbrodt and colleagues [39], who examined (retrospectively) outcomes among ≈ 3000 adult (≥ 40 years old) COPD patients who were using an inhaled corticosteroid/long-acting \( \beta_2 \)-agonist delivered via either pMDI (n = 1960) or DPI (n = 1086) and who had been hospitalized with a diagnosis of COPD exacerbation. pMDI patients were significantly more likely to be prescribed a short-acting \( \beta \)-agonist, experienced more COPD exacerbation-related hospital days and had a greater number of pulmonologist visits compared with DPI patients (p < 0.05 for all), findings prima facie suggestive of greater disease severity. However, multivariate analysis revealed that pMDI patients had a decreased likelihood of a COPD exacerbation-related hospital readmission relative to DPI users and incurred significantly lower all-cause and COPD-related healthcare costs (p < 0.05 for both).

On the other hand, in a recent study, almost all (> 99%) studied patients with asthma or COPD, regardless of age or disease severity, were able to achieve the PIFR of ≥ 30 l/min required for efficient dose delivery through the Easyhaler [40].

Our point in introducing these data is to emphasize that evaluation of inhaler-delivered medications is an uncommonly broad and heterogenous area of medical research characterized by widely varying terminology and criteria: findings vary accordingly and a result to support most points of view can be found if one is prepared to scan the literature in sufficient breadth (see Lavorini et al. [14] for an extensive enumeration and discussion of the clinical dataset). This limitation does not negate any one set of findings, but it recognizes the complexities of the field.

**DISCUSSION**

The sheer range of inhaler devices and the constant enlargement of that range militate against comprehensive head-to-head comparisons of all possible permutations of drug and
device [41]. Some element of judgement and approximation is therefore needed when trying to reach pragmatic conclusions about these matters.

Our own view, shaped by personal experience as well as assessment of the relevant published reports, is that the Easyhaler, as a specific DPI, delivers results that are clinically equivalent or non-inferior to those of pMDIs for the administration of corticosteroid/beta-agonist combination therapy when assessed by lung function criteria. Whether lung function criteria should be the central metric of treatment success, especially in COPD, is beyond the scope of this work but well-founded arguments for other indices have been advanced [42].

We further believe, however, that the value of the Easyhaler lies as much in its practical appeal to patients as in its effects on lung function. A checklist of six criteria for an ‘ideal’ inhaler device has been proposed [43] and it may be said at once that no currently available device meets all the stipulated criteria of effectiveness and reproducibility of drug delivery, precision, stability, comfort, versatility (i.e., allowing the administration of different drugs) and environmental considerations (i.e., absence of chemical contaminants and sustainability).

Interestingly, Ahonen et al. [44] performed a meta-analysis of data from nine clinical trials in asthma ($n = 802$) and reported that the Easyhaler substantially and significantly ($p \leq 0.01$) outperformed both alternative DPI devices or pMDIs on all five nominated indices of device acceptability: ease of use, ease of learning how to use, ease of dosing the drug, ease of inhaling, and overall preference.

Further insights may emerge from an ongoing retrospective, multicenter, non-interventional, observational study (BufoSwitch—NTC04663386). This study enrolls patients with asthma and/or COPD to explore how the authorization of at-pharmacy switching to DPIs containing budesonide–formoterol from June 2018 has affected various aspects of asthma control in Norway.

The focus on pharmacist training in BufoSwitch is a timely reminder that asthma and COPD represent an area of medicine where, to a greater than normal extent, the success of a course of therapy is—quite literally—in the hands of patients. The importance of patient education in optimizing the delivery of inhaled medication has recently been reaffirmed in a prospective cohort study of nurse-based education in COPD patients in South Korea [45]. A similar message was delivered, through different conclusions, by the CRITIKAL study ($n = 3660$) [15], in which critical errors in the use of different types of inhaler were associated with poor clinical outcomes.

An exposition of device-specific and device-critical errors for a very wide range of inhalers can be found in the article by Lavorini et al. [14]. Device-critical errors associated with the Easyhaler include failure to shake the device before use, which may reduce the delivered dose of drug, and failure to hold the device upright when priming.

Patient Education and Patient Preference

Patient preference for a device is also an important consideration and in this context we note two recently completed studies from Spain which used the ‘Feeling of Satisfaction with Inhaler’ (FSI-10) questionnaire to compare asthma patients’ perceptions of the Easyhaler with those of other DPI inhalers or other types of inhaler and which found in each case that patients were more likely to be satisfied with the Easyhaler than with comparator devices [46]. These preferences were apparent in individual domains of the FSI-10, including learning how to use the inhaler, its preparation, its actual use, its weight and size, and its portability [47, 48]. In parallel research in Spain, the cross-sectional, multicenter, observational EFIMIRA study in 1682 asthma patients identified inhaler critical errors in an aggregate of 17% of patients but a significantly lower rate of critical use errors with the Easyhaler than with other devices (10.3 vs. 18.4%; $p < 0.05$). A smaller percentage of patients using the Easyhaler needed technique adjustment compared with comparator devices (34.4 vs. 51.5–68.8%). Critical errors of inhaler use related strongly to poor asthma control (OR 3.03, 95% CI 2.18–4.21) (Fig. 5) [49].
It is clear from all of these lines of evidence that patient education regarding how to store and use their devices correctly should have high priority. Success in this area requires that whoever is responsible for patient education is themselves well versed in the features and limitations of the relevant devices. The Aerosol Drug Management Improvement Team (ADMIT) have provided one useful starting point for this by identifying ten widespread misconceptions about inhaler-based drug delivery [50]. One point identified by ADMIT that we strongly endorse is that, whenever possible, it is reasonable and desirable to restrict regular inhaled medication to a single type of device. The Easyhaler offers six different drugs or drug combinations in several strengths (see Fig. 1). Minimizing the volume of (sometimes contradictory) information and practices that patients have to master and recall can only have a positive influence on adherence and compliance. Simplicity of use extends to the number of daily doses to be delivered, which should be kept to the minimum necessary for optimal therapeutic effect.

Assessment of the patient’s overall status, including age, peak inspiratory flow inhalation volume, and the presence of cognitive or physical limitations, can shape the choice of the most appropriate type of device. From that starting point, the devices within that class may be assessed in more detail. As already noted, all devices are associated with particular usage errors; the relative importance of these will vary between patients and will help to shape choice.

Initial patient education is probably best done face to face, although the particular circumstances of the COVID-19 pandemic may require at least temporary alternative measures and may lead to longer-term changes in the way training is delivered. Certainly, the potential of online videos and similar material as ways of refreshing patient knowledge and proficiency has been highlighted by the impact of COVID-19 and we anticipate further developments in this area and in the associated area of digital monitoring and the management of device errors; some of these health initiatives may currently be speculative but a long-term trend towards such methods seems inevitable. Pending the widespread adoption of such methods, refresher and reminder courses, however delivered, are essential to ensure that patient best practice is encouraged and adhered to.

CONCLUSIONS

All in all, the available data support the assumption that the Easyhaler presents benefits which include consistency of dose [43], achievement of optimal PIFR [51], few critical errors in use [49], and overall high patient satisfaction [33, 37]. Moreover, reduction in emissions of greenhouse gases was shown compared to MDIs. At the same time, it appears from the literature that switching devices to the Easyhaler may improve asthma/COPD control and can be done without any additional risks.

Limitations and Knowledge Gaps

When a patient is suffering from uncontrolled asthma or COPD, multiple underlying issues may give rise to the decision to switch inhalers. These include adherence issues, poor inhaler technique, patients’ health, adverse events, patient preferences, and cost considerations.
The common understanding is that switching devices should not be advocated for patients unless they suffer from uncontrolled asthma or COPD, and that this change requires a careful process including patient consent, clinical assessment, patient discussion, device retraining, and follow-up [7]. However, at a population level, there is evidence that switching to ‘an equivalent’ inhaler in patients with COPD and asthma does not negatively affect patients’ health or healthcare utilization. Indeed, disease control seems to improve, perhaps due to an increased awareness of inhalers, which improves compliance [52].

There are, however, inherent difficulties with systematic clinical trials of inhaler switching due to difficulties in blinding, the need for re-education, balancing of arms with regard to inspiratory force, and patients’ personal abilities and preferences [7]. The various studies summarized in Table 1 identify the Easyhaler as a credible option when a switch of drug-delivery device is mooted, but it has to be acknowledged that this is an area of respiratory medicine in which well-configured randomized trials are lacking and that many of those that have been conducted (e.g., Syk et al. [53]) quantify success in terms of disease symptom control. While that is a legitimate outcome, it reveals little direct insight into the relative acceptability of devices for patients or about the factors that shape patients’ perceptions of a given device as being more or less acceptable than comparators. The influence of the circumstances of switching for non-medical reasons (e.g., withdrawal of specific drugs or drug combinations or mandatory/discretionary branded to generic substitutions) can also further complicate appraisal of relative device acceptability.

ACKNOWLEDGEMENTS

Funding. No funding or sponsorship was received for this study. As it regards the publication of this article, Orion Pharma agreed to fund the Rapid Service Fee.

Medical Writing and/or Editorial Assistance. We thank Piero Pollesello (Orion Pharma, Finland) for editorial coordination among co-authors, Shrestha Roy (Orion Pharma, India) for the graphic renditions, Hughes associates (Oxford, UK) for editorial assistance with the English language, and Alexander J.K. Wilkinson (Respiratory Department, East and North Hertfordshire NHS Trust, Stevenage, UK) for useful discussion.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. FL, JC, GG, AP-S, ASP, PR, JS, MS, LT, AX, and TH contributed to the concept and design and drafting the manuscript.

Disclosures. As it regards relevant conflict of interest for this publication, FL, JC, GG, AP-S, ASP, PR, JS, MS, LT, AX and TH report that, in the latest 5 years, they have received either research grants and/or speaker honoraria and/or support for conference attendance from Orion Pharma, where the Easyhaler was developed. PR is a full-time employee of Orion Pharma.

Compliance with Ethics Guidelines. This review is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated

△ Adis
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


